- Latin America
- United Kingdom - Solicitors
- United Kingdom - The Bar
- United States
- What is the GC Powerlist?
- How to nominate in-house counsel
- Australia/New Zealand
- Asia Pacific
- Latin America
- Middle East
- United Kingdom
- United Kingdom Teams
- United Kingdom - Rising Stars
- United States
- United States - Rising Stars
- United States Teams
- Client Intelligence Report
- Up in the air
- Bridging the Gulf
- Litigation and regulatory challenges in financial services
- AI and the law tools of tomorrow
- Scottish GCs
- North West clients
- Pan-Europe bribery crackdown
- Arbitration backing Africa's investment boom
- Gaining access to North Africa
- Anti-corruption in Asia
- Business thinking
- In-house management
- Career path
- Legal perspective
- Big picture
- In discussion
- Interrogating value
- GC interviews
- Our great leader: unravelling the process of choosing the right candidate for the top job
- The promised land? Big data and
the in-house lawyer
- Law: a risky business?
- Playing to your strengths: building diversity of thought into business
US Special Edition Downloadable PDF
- Dissenting perspectives
- Developments in Panama
- The international arbitration summit
- The Global 100 debate - Chasing Alpha
- Cyber security
- North Africa - through the gate
- North West Clients
- Scottish GCs
- The Global London debate
- Law firm leaders
- Cyber in-security
- Legal Business commercial litigation summit
- Funding disputes
- GC Powerlist roundtable - Germany
- GC roundtable - talent management
- GC Powerlist roundtable - Brazil
Search News and Articles
Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
One of the most important negotiated points by parties in contract negotiations is the dispute resolution clause. If parties agree on arbitration, they often negotiate which arbitration institution or arbitration rules will apply in resolving potential disputes.
Ren Qing and Wu Peng, Partners in Zhong Lun Law Firm
By Steve Zhao
On April 30, 2015, OmniVision Technologies, Inc. (OVTI, a Delaware company listed on NASDAQ) announced that it has entered into a definitive agreement to be acquired by a consortium composed of Hua Capital Management Co. Ltd. (“Hua Capital Management”), CITIC Capital Holdings Limited (“CITIC Capital”) and GoldStone Investment Co. Ltd. (“GoldStone Investment”) (collectively, the “Consortium”). Under the terms of the agreement, OmniVision stockholders will receive $29.75 per share in cash, or a total of approximately $1.9 billion. The agreement was unanimously approved by OmniVision’s Board of Directors.
Audry Hong Li, Partner of Zhong Lun Law Firm*
In February 2014, the China Food and Drug Administration (“CFDA”) invited second-round comments from the public regarding proposed amendments to the China Drug Registration Regulations (“DRR”). One of the proposed amendments touches upon patent protection for drugs in China.
The National Development and Reform Commission ( NDRC ) released a new set of Management Measures for Approval and Filing of Outbound Investment Projects ( 境外投资项目核准和备案管理办法) ( New Measures ) on 8 April 2014. The New Measures take effect on 8 May 2014 and will replace the Interim Management Measures for Approval of Outbound Investment Projects ( 境外投资项目核准暂行管理办法) ( Original Measures ) which have been in force since 9 October 2004.
On 21 March 2014, CIRC issued the Administrative Measures on the Acquisition and Merger of Insurance Companies (the Insurance M&A Measures ) which will take effect from 1 June 2014. The Insurance M&A Measures apply to M&A activities whereby an insurance company is the target for a merger or acquisition. The target insurance company could be either a domestic or a foreign invested insurer. However, the Insurance M&A Measures will not apply to any equity investment by insurance companies in non-insurance companies in China or in overseas insurance companies.
The Regulations on Supervision and Administration of Medical Devices (in Chinese《医疗器械监督管理条例》, State Council Order No. 650) (the Medical Device Regulations) were amended by China's State Council on 31 March 2014 and will come into effect on 1 June 2014. This is the first amendment in more than a decade since the Medical Device Regulations were first promulgated in 2000, even though the amendment was initiated eight years ago in 2006. The 2014 amendment unveils reforms on the regulatory regime for medical devices market in China from various aspects.
Walking a fine line in China:Distinguishing between legitimate commercial deals and commercial bribeChina in the 21st century exemplifies an atmosphere of great opportunity and intense competition. Against this backdrop, it has become increasingly common for businesses to adopt a variety of practices in order to make their products and services competitive. Such practices may include paying middle-men to promote sales and giving incentives to buyers directly. However, whilst revenue spikes are undoubtedly welcome, businesses should bear in mind the potential backlash arising out of these commercial arrangements. The risk that such arrangements may not comply with anti-bribery and corruption laws and therefore cause business significant damage in the long term should not be underestimated.